Australian clinical-stage biotech Neurizon Therapeutics (ASX: NUZ & NUZOA), which is advancing innovative treatments for neurodegenerative diseases, has significantly strengthened its executive management team with three key appointments.
These include Kathryn Williams as chief regulatory officer (CRO), Dr Jeffrey Brown as chief scientific advisor (CSA), and Dr Chris Freitag as chief medical advisor (CMA).
Neurizon says these appointments provide the company with broader expertise in regulatory affairs, clinical development and commercialisation, and will assist in accelerating Neurizon’s stated strategy to advance its lead drug candidate, NUZ-001’s clinical development pathway, secure regulatory approvals, expand the pipeline in neurodegenerative diseases and optimize future market access. The combined expertise of Ms Williams, Dr Brown, and Dr Freitag will assist in the company’s near-term focus to lift the clinical hold for NUZ-001’s investigational new drug (IND) application to facilitate entry into the HEALEY ALS Platform Trial in H2 CY2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze